Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor–mutant non-small cell lung cancer with brain metastases
F Yu, J Ni, W Zeng, Y Zhou, T Guo, Y Zeng… - International Journal of …, 2021 - Elsevier
… Overall survival (OS), progression-free survival (PFS), and the time to intracranial progression
(iTTP) were compared between the 2 groups, with adjustment by covariates in propensity-…
(iTTP) were compared between the 2 groups, with adjustment by covariates in propensity-…
Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases
J Wang, Z Liu, Q Pang, T Zhang, X Chen, P Er, Y Wang… - BMC cancer, 2020 - Springer
… brain metastases (BMs), but this system does not take into account the epidermal growth factor
receptor (EGFR) mutations… We defined intracranial progression-free survival (iPFS) as the …
receptor (EGFR) mutations… We defined intracranial progression-free survival (iPFS) as the …
[HTML][HTML] … different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
… advanced EGFR-mutant NSCLC were included. The efficacy against brain metastasis was
… and non-irradiated brain metastases, central nervous system progression-free survival (CNS…
… and non-irradiated brain metastases, central nervous system progression-free survival (CNS…
Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
W Zhao, W Zhou, L Rong, M Sun, X Lin, L Wang… - Frontiers in …, 2022 - frontiersin.org
… (NSCLC) with epidermal growth factor receptor (EGFR) mutations has a high incidence of
brain metastases (BMs). However, the association between EGFR mutations and BMs remains …
brain metastases (BMs). However, the association between EGFR mutations and BMs remains …
[HTML][HTML] Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different …
H Xu, H Chen, J Kong, Y Zhang, S Liu… - Annals of …, 2021 - ncbi.nlm.nih.gov
… ) were evaluated, along with progression-free survival (PFS) … Of patients with epidermal
growth factor receptor-mutated (… 34.2% to 52.9% develop brain metastases during treatment (1). …
growth factor receptor-mutated (… 34.2% to 52.9% develop brain metastases during treatment (1). …
Local ablative radiotherapy on oligo‐progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non–small cell lung …
… -generation epidermal growth factor receptor tyrosine kinase … efficacy in prolonging
progression-free survival in advanced … the other had whole brain radiotherapy on brain …
progression-free survival in advanced … the other had whole brain radiotherapy on brain …
… between first-, second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer and brain …
S Caponnetto, O Cantale, A Friedlaender… - Journal of Molecular …, 2021 - mdpi.com
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor
(EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the …
(EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the …
… -brain radiotherapy can improve the survival of patients with multiple brain metastases from non-small cell lung cancer treated by epidermal growth factor receptor …
C Chen, Y Wu, BL Liu, HW Wang, JH Ma… - Cancer Management …, 2020 - Taylor & Francis
… the survival of EGFR-mutated NSCLC patients. Citation5,… the effect of intracranial metastases
control is good, brain RT … Intracranial progression-free survival was defined as the time …
control is good, brain RT … Intracranial progression-free survival was defined as the time …
[HTML][HTML] Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from …
Y Yu, J Qian, L Shen, W Ji, S Lu - Annals of Translational Medicine, 2022 - ncbi.nlm.nih.gov
… epithelial growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
with brain … (20) found that icotinib alone achieved significant intracranial progression-free …
with brain … (20) found that icotinib alone achieved significant intracranial progression-free …
… kinase inhibitors used in treating EGFR-mutant pulmonary adenocarcinoma with brain metastasis and intracranial intervention have no impact on clinical outcomes
… Brain metastasis is a factor of a poor prognosis in patients with non-small-cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The … progression-free …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The … progression-free …